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“The more I study the sloth the more it reminds me of science: 
The method might look slow and sometimes inefficient, but in fact 
it optimises resources in an astonishing way and combined with 
determination leads to result.” 
Horatio S. Darwin, British physician and naturalist 
 
  
  
  
ABSTRACT 
Multiple myeloma (MM) is an incurable disease with an increasing number of treatment 
options. The introduction of what are called novel drugs (bortezomib, lenalidomide and 
thalidomide) was an important step. These treatments have been well studied in clinical trials 
that involve selected patient groups and that focus on a specific treatment in a specific line of 
treatment. However, there is scarce information on the survival as a function of the entire 
treatment sequence. We wanted to clarify the effect of these treatments in a real-life setting. 
Furthermore, there are several well-known prognostic factors for MM, but the impact of 
those factors on survival in the era of novel treatment is not fully understood. In this thesis we 
aimed to: 1) understand in which order the treatments should be given, 2) define factors 
affecting prognosis, 3) increase the knowledge of cytogenetic abnormalities and their 
influence on prognosis and choice of treatment. 
In Paper I, we retrospectively analysed the outcome in high-dose treated (HDT) patients. 
The patients were divided according to induction therapy. 142 patients had received 
conventional chemotherapy with either vincristine, doxorubicin, dexamethasone (VAD) or 
cyclophosphamide, betamethasone (CyBet) and 94 patients had received bortezomib, 
cyclophosphamide, betamethasone (VCB). We found that the VCB patients had a quicker 
and better response than the VAD/CyBet group as well as a longer time to progression. 
In Paper II, we investigated 1 638 consecutive MM patients and compared their survival 
with that of a sex- and age-matched normal population. The use of novel agents as upfront 
treatment in non-HDT patients resulted in a significantly longer overall survival (OS) 
compared to those who received conventional chemotherapy. The OS was further improved 
by using novel agents in both first and second line of treatment and for these patients the OS 
approached the survival in the matched normal population. Paper III focused on MM 
patients with renal impairment at diagnosis. Previous studies have demonstrated the negative 
impact of renal impairment when conventional chemotherapy is used. We could confirm 
these findings. However, novel agents significantly improved the OS of non-HDT patients 
with renal impairment. Moreover, the difference in survival between those with and those 
without renal impairment vanished with the use of novel agents. Despite high response rates 
to novel treatment, approximately 20% of the patients do not respond to bortezomib therapy. 
In Paper IV, we demonstrated that changes associated with del(8)(p21) might be one 
explanation to bortezomib resistance. We found that MM cells without del(8)(p21) responded 
to bortezomib treatment by upregulating the pro-apoptotic TRAIL receptors, thus making the 
cells more sensitive to TRAIL/APO2L-mediated apoptosis. However, in cells with 
del(8)(p21) no upregulation was seen and the cells were largely resistant to TRAIL/APO2L-
mediated apoptosis. These findings were also supported by clinical observations. 
To summarize, with these studies we could confirm that the survival benefits with 
bortezomib, lenalidomide and thalidomide that have been demonstrated in clinical trials are 
also seen in real life. Furthermore, we demonstrate a possible resistance mechanism to 
bortezomib.   
POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Multipelt myelom är en cancersjukdom som utgår från benmärgens plasmaceller. 
Plasmaceller är en typ av vita blodkroppar (B-celler) som är viktiga för immunförsvaret. 
När plasmacellerna träffar på till exempel virus och bakterier börjar de tillverka antikroppar 
(immunglobuliner) som tar död på inkräktarna. Vid myelom har plasmacellerna blivit sjuka 
och börjat föröka sig onormalt mycket. Dessutom börjar de tillverka ett speciellt 
immunglobulin som kan mätas i blodet och/eller i urinen och som kallas M-komponent. 
Det är denna M-komponent man följer när man kontrollerar behandlingssvaret hos en patient. 
Dock finns det myelompatienter som inte utsöndrar någon M-komponent och hos dessa får 
man följa sjukdomen på annat sätt. Hos vissa patienter tillverkar myelomcellerna bara delar 
av immunglobulinet, de så kallade lätta kedjorna, och dessa kan man också mäta i blodet. 
Det finns även en liten grupp patienter som inte utsöndrar vare sig M-komponent eller lätta 
kedjor. Man blir då mer beroende av att ta upprepade prov från benmärgen för att kontrollera 
sjukdomsstatus. 
I Sverige insjuknar varje år drygt 600 personer och de flesta av dessa är över 65 år. 
Myelom utgör cirka 2 % av alla dödsfall orsakade av cancer och 20 % av alla dödsfall 
orsakade av blodcancersjukdomar. Myelomcellerna kan producera ämnen som i sin tur 
stimulerar nedbrytning av skelettet, vilket ofta leder till smärta. Andra tecken på myelom är 
trötthet, infektions- och blödningsbenägenhet samt nedsatt njurfunktion. Ofta upptäcks dock 
sjukdomen via rutinprovtagning på vårdcentralen innan symptom hunnit uppkomma.  
Behandling påbörjas först när sjukdomen börjar ge symptom, varför en del patienter kan vara 
behandlingsfria under lång tid. Yngre patienter, det vill säga de som är under 65 till 7 0 år, 
genomgår oftast så kallad högdosbehandling (HDT). Denna behandling blir effektivare om 
man först eliminerar så många myelomceller som möjligt. Därför får patienterna först 3 till 4 
behandlingar med andra läkemedel (så kallad induktionsbehandling). Sedan samlas 
stamceller från patienten in och fryses ner och avslutningsvis får patienten en extra stark 
cytostatikakur, det vill säga HDT. För att påskynda benmärgens återhämning och minska 
risken för att patienten dör i komplikationer ger man tillbaka patientens egna stamceller 
(autolog stamcells-transplantation). Äldre patienter och multisjuka patienter klarar dock inte 
av denna behandling utan får istället olika kombinationer av läkemedel. 
De senaste 10 till 15 åren har det skett en snabb utveckling av läkemedel. Framförallt har de 
tre läkemedlen bortezomib, talidomid och lenalidomid spelat en stor roll för prognosen. 
Trots detta är myelom fortfarande en obotlig sjukdom. Det beror på att en del cancerceller 
överlever behandlingen och orsakar återfall. Därför krävs det upprepade behandlingar med 
olika läkemedelskombinationer. 
Informationen om hur effektivt ett nytt läkemedel är kommer från kliniska prövningar. 
Dessa prövningar inkluderar oftast endast en utvald grupp av patienter som inte alltid speglar 
den grupp av patienter som i slutändan kommer att få behandlingen. Dessutom fokuserar 
  
dessa studier på en specifik behandling i ett visst skede av sjukdomen och tar inte hänsyn till 
vilka behandlingar som givits före och efter. Vi ville därför studera hur väl de nyare 
läkemedlen fungerar för de patienter som behandlas i den kliniska vardagen. Dessutom ville 
vi ta reda på om det spelar roll i vilken ordning de olika läkemedlen ges.  
Förutom behandlingen finns det flera andra faktorer som påverkar prognosen. 
Dessa inkluderar njurfunktion, blodvärde och skelettpåverkan. Det är dock inte helt klarlagt 
vilken effekt dessa faktorer har på prognos och överlevnad sedan de nyare läkemedlen, 
det vill säga bortezomib, lenalidomid och talidomid, introducerades på marknaden. 
Dessutom har studier funnit olika kromosomavvikelser som påverkar prognosen vid myelom. 
Vår grupp har tidigare demonstrerat att patienter med avsaknad av den korta armen på 
kromosom 8 (del(8)(p21)) har en sämre prognos, men orsaken till detta är inte klarlagd. 
Vi ville därför studera prognosfaktorer för att få en tydligare bild av deras betydelse i skenet 
av de behandlingsalternativ som finns tillgängliga. Likaså ville vi förstå varför del(8)(p21) 
påverkar prognosen och svaren på olika behandlingar. 
I de tre första studierna gick vi igenom patientjournaler för att samla in data kring behandling 
samt svar på behandling. Den första studien innefattade 236 patienter som man hade för 
avsikt att ge HDT. Tidigare gav man endast konventionell cytostatika som 
induktionsbehandling inför HDT. Sedan de nyare läkemedlen introducerats har dessa dock 
tillfogats behandlingen. I Sverige använder man huvudsakligen en kombination där 
bortezomib ingår. Vi var därför intresserade av huruvida denna behandling gav lika god 
effekt i verkligheten som man sett i kliniska studier. Vi fann att patienter som fått bortezomib 
fick ett både snabbare och bättre svar på induktionsbehandlingen, och behandlingssvaret 
varade dessutom längre hos bortezomibpatienterna. 
I andra och tredje delarbetena analyserade vi data från 1638 myelompatienter som behandlats 
på femton olika sjukhus i Sverige. Patienterna delades in i de som genomgått HDT (HDT-
gruppen) och de som inte genomgått HDT (icke-HDT-gruppen). Den viktigaste slutsatsen 
från den andra studien var att icke-HDT-patienter som fått bortezomib, talidomid eller 
lenalidomid i första linjens behandling hade en tydligt förlängd överlevnad jämfört med dem 
som endast fått konventionell cytostatika. Vi kunde alltså bekräfta vad man tidigare sett i 
kliniska prövningar. Dessutom fann vi att överlevnaden förlängdes ytterligare om man 
använde dessa nyare läkemedel även när patienten fick återfall. I HDT-gruppen kunde vi 
dock inte se samma positiva effekt på överlevnaden.  
Med tanke på det senaste årtiondets framsteg inom myelombehandling var vi nyfikna på 
överlevnaden hos myelompatienter i relation till överlevanden i normalbefolkningen och 
jämförde därför dessa två (studie II). Vi kunde konstatera att myelompatienter tyvärr 
fortfarande har en klart sämre överlevnad än den svenska normalbefolkningen. Dock fann vi 
att äldre myelompatienter som erhållit nyare läkemedel både i första och andra 
behandlingsomgången började närma sig överlevnaden i normalbefolkningen.  
Tredje delarbetet fokuserade på de patienter som hade njursvikt vid diagnostillfället. 
Flera tidigare studier hade visat att detta var en negativ faktor och att dessa patienter hade 
sämre överlevnad än de som hade normal njurfunktion vid behandling med konventionell 
cytostatika. Detta bekräftades också i vår studie. Dock fann vi att den prognostiska betydelsen 
av njursvikt för icke-HDT-patienter försvann om patienterna fick behandling med 
bortezomib, talidomid eller lenalidomid. Efter behandling med dessa nyare läkemedel hade 
patienterna med njursvikt samma överlevnad som de med normal njurfunktion. 
Trots den goda effekten av bortezomibbehandling fungerar i dagsläget inte denna hos cirka 
20% av myelompatienterna.  
I den fjärde och sista studien visade vi att förändringar kopplade till del(8)(p21) kan vara en 
av orsakerna till bortezomib-resistens. Bortezomibs myelomdödande funktion beror delvis på 
att detta läkemedel får myelomceller att öka antalet ”dödsreceptorer” på sin cellyta, det vill 
säga uppreglerar receptorerna, så att immunförsvaret i sin tur kan döda cancercellerna. 
Vi fann att denna uppreglering av receptorer inte skedde i myelomceller med del(8)(p21), 
vilket resulterade i att färre myelomceller dog. Vi kunde också se att dessa fynd stämde 
överens med kliniska observationer. 
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1 BACKGROUND 
1.1 EARLY HISTORY 
The first well documented case of multiple myeloma (MM) was published in 1844 by 
Dr. Solly who described a 39-year-old woman with fatigue, severe bone pain and repeated 
fractures. She died four years after the onset of symptoms and the post-mortem examination 
revealed that a red substance had replaced the cancellous portion of the sternum as well as 
both femurs. The bone marrow (BM) cells were found to be very clear and oval-like with one 
or sometimes two bright nucleoli [1]. In 1850 Dr. Macintyre described one of his patients, 
a man who, at the age of 45, had consulted Dr. Macintyre five years earlier due to 
excruciating pain and fatigue. Because of oedema, Dr. Macintyre examined the urine from 
the patient and found it to “abound in animal matter” [2]. A sample of the urine was also sent 
to Dr. Bence Jones who described that the urine contained large quantities of a substance that 
resembled albumin, but differed from albumin in many ways [3] and this urinary protein was 
later named after Dr. Bence Jones. When the patient died in 1846 the autopsy showed that 
similarly to Dr. Solly’s patient a “red geletiniform substance” consisting mainly of large 
nucleated round or oval-shaped cells with a bright nucleolus filled the cancellous cavities [4]. 
The cells described in both these cases were most likely malignant plasma cells. Several more 
cases followed [5] and in 1873 the term “multiple myeloma” was introduced by von Rustizky 
who, during autopsy of a 47-year-old man, found eight separate tumours of BM that he called 
multiple myeloma [6] and in 1900 Wright described that MM consisted of plasma cells [7]. 
1.2 PATHOGENESIS 
1.2.1 Normal B cell development 
The immature B cells express cell-surface immunoglobulin (Ig) M with kappa or lambda 
light chains (IgM-kappa or -lambda) and develop in the BM from a lymphoid progenitor cell 
[8]. The immature B lymphocytes can leave the BM and migrate to the spleen where they 
mature and become IgM- and IgD-expressing B cells [8-10]. The majority of these cells 
become circulating naïve follicular B cells, but a fraction of the cells stay in the spleen as 
non-circulating marginal-zone B cells, Figure 1 [9]. 
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Figure 1. The development of B cells. HSC, haematopoietic stem cell; BCR, B cell receptor. Reprinted by permission 
from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY [9], copyright 2005.  
 
On encounter with antigen, the marginal-zone B cells respond rapidly by proliferating and 
differentiating to short-lived plasma cells, Figure 2. Short-lived plasma cells can also be 
produced from circulating naïve follicular B lymphocytes. Thus, both B cells in the marginal 
zones and in the follicules are involved in the early extrafollicular response in which plasma 
cells that lack somatically mutated Ig genes are produced. These plasma cells are important 
for the initial response to pathogens, but they only secrete low-affinity IgM antibodies and are 
short-lived [8].  
However, activated follicular B cells can also enter the follicles in the lymph node and give 
rise to germinal centres. In the germinal centres, the B cells proliferate and differentiate, 
resulting in long-lived plasma cells and memory B cells with high-affinity B cell receptors 
[8,9]. The long-lived plasma cells are terminally differentiated and can no longer proliferate. 
They move to the BM in order to find a survival niche where they can live for many months 
[8,11,12]. 
© 2005  Nature Publishing Group 
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from the marginal zone to the bridging channels and the
red pulp of the spleen, where they undergo a burst of
proliferation. This occurs concomitantly with differenti-
ation to form foci of plasmablasts7, which secrete
immunoglobulin but continue to proliferate.
A crucial property of marginal-zone B cells is their
inherent ability to respond rapidly to antigen. They have
a lower threshold for antigen activation than follicular 
B cells and, when stimulated with lipopolysaccharide
(LPS), pr oliferate to a greater extent9. T he molecular
mechanisms that are responsible for the increased
responsiveness of marginal-zone B cells are not fully
understood, but expression ofincreased levels of cell-
surface molecules — such as CD21 (also known as
complement receptor 2), CD1d (an MHC-class-I-like
molecule that presents lipid antigens), CD38 (also
known as ADP-ribosyl cyclase) and theco-stimulatory
molecules CD80 and CD86 — is likely to facilitate anti-
gen capture and T-cell co-stimulation9,10. I n addition,
differences in the levels of transcriptional regulators and
signal-transduction molecules are likely to be important.
Ci rculating mature follicular B cells that both
encounter antigen and receive help from T cells also
respond rapidly (albeit more slowly than marginal-zone
B cells), undergoing proliferation and plasmacytic differ-
entiation to form extrafollicular foci of plasmablasts and
plasma cells. Two days after immunization with a T-cell-
dependent antigen, foci are observed along the periphery
of the periart riolar lymphoid sheath. These foci expand
until day 8 after immunization and then diminish11.
Plasma cells formed by either marginal-zone or follicular
B cells in this early extrafollicular response do not have
SOMATICALLY MUTATED immunoglobulin genes and are
short-lived, undergoing apoptosis in situ12. However,
these cells provide a rapid initial response to pathogens.
Post-germinal-centre response.When follicular B cells
both encounter antigen and receive T-cell help, a second
developmental possibility is the establishment of a ger-
minal centre13,14. Germinal centres are specialized areas
Mi ce that lack marginal-zone B cells are susceptible to
bacterial infections8, underscoring the importance of
marginal-zone B cells for mounting an immune
response to bacteria. Consistent with this, marginal-zone
B cells have a rep rtoire that is skewed towards recogni-
tion of T- CELL-INDEPENDENT TYPE 2 (TI-2) ANTIGENS , although
some of these cells recognize T-cell-dependent antigens
and therefore present antigen and provide co-stimulation
to T cells. The location of naive marginal-zone B cells,
which do not circul te, facilitates early encou ter with
blood-borne antigens. Within a few hours ofimmuniza-
tion with a TI-2 antigen, marginal-zone B cells moveT- CELL-INDEPENDENT TYPE 2
ANTIGENS
(TI-2 antigens). Antigens that
contain multiple identical
epitopes, which crosslink B-cell
receptors.
SOMATICALLY MUTATED
Immunoglobulin genes that
have undergone somatic
hypermutation (SHM). SHM is
a unique mutation mechanism
that is targeted to the variable
regions of rearranged
immunoglobulin gene
segments. Combined with
selection for B cells that produce
high-affinity antibody, SHM
leads to affinity maturation of
B cells in the germinal centre.
ANTIBODY-SECRETING CELLS
(ASCs). Denotes both
proliferating plasmablasts and
non-proliferating plasma cells.
The term is used when both cell
types might be present.
Box 1 | B1 cells
B1 cells are mainly found in the peritoneal and pleural cavities and the gut lamina propria. They give rise to ANTIBODY-
SECRETING CELLS (ASCs), but they differ from conventional B cells (B2 cells) in several interesting ways115. They have a
unique cell-surface phenotype, including expression of CD5 (by the B1a but not the B1b subset) and CD11b (in the
peritoneal and pleural cavities). B1-cell progenitors are abundant in the fetal liver, but are absent in the adult bone
marrow116. B1 cells have a unique self-renewing capacity and express a B-cell receptor (BCR) repertoire that is skewed
towards recognition of T-cell-independent type 2 (TI-2) antigens. They are responsible for the production of ‘natural’
IgM, which forms in response to self-antigens but often recognizes bacterial antigens and provides the first line of
defence by antibodies against such pathogens. The spleen is required for the generation and maintenance of B1a cells117.
When B1 cells become activated in the pleural or peritoneal cavities, they migrate to the spleen or gut, lose expression 
of CD5 (which negatively regulates signalling through the BCR) and become antibody-secreting plasma cells118,119.
Tr anscription of CD5 is controlled by a nuclear factor of activated T cells (NFAT)-dependent enhancer, and development
of B1a cells in both the peritoneal cavity and the spleen requires NFATc1 but is independent of NFATc2 (REF. 120) . B1 cells
have constitutively activated STAT3 (signal transducer and activator of transcription 3)121, whereas in B2 cells, STAT3 is
activated only in response to signalling through cytokine receptors or Toll-like receptors. B1 cells that become ASCs use
part of the same gene-expression programme as B2 cells to secrete antibody, because although B-lymphocyte-induced
maturation protein 1 (BLIMP1) is not required for the formation of B1 cells, it is required for the ability of these cells to
secrete antibody (D. Savitsky and K.C., unpublished observations).
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Figure 1 | Antigen-independent development of B cells. B cells develop from pluripotent stem
cells in the bone marr w, where full ommitment to the B-cell lineage requires the transcription
factor paired box protein 5 (PAX5). Naive B cells that exit the bone marrow continue to undergo
maturation in the spleen to form long-lived naive follicular B cells and, to a lesser extent, naive
marginal-zone B cells. BCR, B-cell receptor; HSC, haematopoietic stem cell; pre-B cell, precursor
B cell; T1, transitional stage 1; T2, transitional stage 2.
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Figure 2 Formation of plasma cells. CSR, class-switch recombination. Reprinted by permission from Macmillan 
Publishers Ltd: NATURE REVIEWS IMMUNOLOGY [9], copyright 2005. 
1.2.2 Origin of the multiple myeloma cells 
MM cells are clonally expanded plasma cells but the exact origin of the MM cells is not fully 
understood. Studies have suggested that plasma cells lack proliferative capacity. Instead, 
there is evidence that the MM cells arise from a population of myeloma cancer stem cells that 
resemble memory B cells. These cells are thought to initiate disease, and to be the cause of 
progression and relapse [12,13]. However, it should be noted that some studies indicate that 
the malignant plasma cells themselves are tumorigenic and that they can proliferate [13]. 
1.2.3 Bone marrow microenvironment 
The MM microenvironment consists of a cellular component, extracellular matrix (ECM), 
adhesion molecules, cytokines and growth factors, Figure 3. This is crucial for the growth, 
spread and survival of plasma cells and affects drug resistance and relapse [14,15]. 
The homing of MM cells to the BM is achieved with the help of cytokines that bind to MM 
cells, thus inducing motility and cytoskeletal rearrangements. In the BM, various adhesion 
molecules take part in the binding of MM cells to ECM and to BM stromal cells (BMSCs) 
[12,16]. 
© 2005  Nature Publishing Group 
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BCRs and express switched immunoglobulin isotypes,
exit the germinal centre.
Memory-cell response.Post-germinal-centre memory 
B cells retain high-affinity BCR at their cell surface, do
not secrete antibody and (at least one subset) can persist
independently of antigenic stimulation when gene tar-
geting is used to change the specificity of the BCR20,21.
Memory B cells have the intrinsic ability to respond
more rapidly than naive B cells, and they show a prolif-
erative burst on secondary encounter with antigen22.
Complement receptors expressed by stromal cells are
required for this rapid recall response19. Stimulation of
human memory B cells ex vivoshows that bystander 
T- cell signals and CPG-CONTAINING OLIGODEOXYNUCLEOTIDES
can suffice to stimulate the differentiation of memory 
B cells, indicating a way to replenish and/or maintain
memory and plasma cells in the absence offurther
exposure to antigen23.
A unique subset of BCR+CD79b+B220–syndecan 1
(SDC1) – cells in the bone marrow was shown by adop-
tive transfer to be ‘pre-plasma’ memory cells; these cells
differentiate into plasma cells on secondary encounter
with antigen more readily than do the B220+ memory
subset in the spleen24. However, this pre-plasma memory-
cell subset is controversial because another research
group has suggested that they are non-B cells that cap-
ture BCRs using cell-surface Fc receptors25. BCR +B220low
SDC1+CD44+ bone-marrow cells that differentiate into
plasma cells independent of antigen have also been
described26. T he relationship between these two bone-
marrow cell populations is unresolved at present. The
common requirement for B-lymphocyte-induced mat-
uration protein 1 (BLIMP1 ) in the formation of plasma
cells and pre-plasma memory cells led us to speculate
that post-germinal-centre cells might develop through 
a single pathway that leads from memory B cells to
plasma cells27. T he alternative possibility is that memory
B cells and plasma cells are two separate fates of the B cells
that leave the germinal centre.
Relationships between cell division and plasma-cell 
differentiation.Before differentiation into plasma cells,
activated B cells undergo a strong proliferative burst.
Studies using a division-tracking dye to assess cell divi-
sions of B cells stimulated in vitroshowed that, at each
cell division, there was a probability of commitment to
the plasmacytic fate, and this probability was increased in
the presence ofinterleukin-4 (IL-4) or IL-5 (REFS 28,29) .
Clearly, the clonal expansion of cells that are committed
to a plasma-cell fate amplifies the selected antibody
response, but these studies indicate that proliferation
might be a mechanistic requirement for plasmacytic dif-
ferentiation. Because replication provides an opportu-
nity for epigenetic remodelling, it will be interesting to
study unactivated B cells and examine the chromatin
structures of the genes that are crucial for plasma cells.
Ultimately, proliferation ceases and non-dividing plasma
cells are formed, but it is interesting that BLIMP1
expression and immunoglobulin secretion precede the
cessation of the cell cycle.
in the follicle where B cells undergo rounds of prolifera-
tion, which is accompanied by affinity maturation and
CLASS-SWITCH RECOMBINATION (CSR) ofimmunoglobulin.
Antigen-specific T helper cells and FOLLICULAR DENDRITIC
CELLS (FDCs) are important for the germinal-centre
response15. Interactions between CD40 ligand (CD40L)–
CD40 and inducible T-cell co-stimulator (ICOS)–ICOS
ligand — which are present at the cell surface of T and 
B cells, respectively — are important, as are cytokines
expressed by T cells16. T  helper cells present in the germi-
nal centre have unique properties, including high-level
expression of CXC-chemokine ligand 13 (CXCL13) 17
and the adaptor protein SAP (signalling lymphocyte-
activation molecule (SLAM)-associated protein), which
is required for providing help18. FDCs sequester antigen
in the germinal centre, and complement receptors
(CD21 and CD35) expressed by FDCs are crucial for
this function19. T he germinal-centre response peaks
between day 10 and day 14 after immunization and
then diminishes. Plasma cells and memory B cells,
which mainly have somatically mutated, high-affinity
CLASS-SWITCH
RECOMBINATION 
(CSR). A DNA rearrangement 
in which deletion replaces one
immunoglobulin heavy-chain
constant-region gene segment
(usually μ) with a more 3ʹ gene
segment (γ, ε or α).
FOLLICULAR DENDRITIC CELLS
(FDCs). Specialized cells of
unknown origin, which hold
antigen–antibody complexes in
germinal centres and are crucial
for optimal selection of B cells
that produce antigen-binding
antibody.
CPG-CONTAINING
OLIGODEOXYNUCLEOTIDES 
DNA oligonucleotides that
contain unmethylated CpG
bases, which are commonly
found in bacteria.
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Figure 2 | Formation of plasma cells. Antibody-secreting cells (ASCs) formed from B1 cells
secrete natural antibody in the absence of external antigen, and they also secrete IgA in the gut,
in response to pathogens. On encounter with foreign antigen (indicated by week 1 in figure), naive
marginal-zone B cells differentiate into plasma cells, and subsequently, naive follicular B cells also
differentiate into plasma cells. Most of the extrafollicular plasma cells that are formed in this early
response are short-lived. Some activated follicular B cells form a germinal centre. Post-germinal-
centre plasma cells might progress through a memory B-cell stage in the primary response or
might develop directly from germinal-centre B cells (for further details, see main text). Plasma cells
that result from a germinal-centre reaction might become long-lived if they find survival niches,
which are mainly located in the bone marrow. CSR, class-switch recombination.
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1.2.3.1 Extracellular matrix 
The ECM is composed of proteins, proteoglycans and glycosaminoglycans [15]. 
Myeloma cells adhere to the ECM, which leads to adhesion, migration and spread of the 
disease. In addition, these interactions can also give rise to what is called cell adhesion-
mediated drug resistance. It is a spontaneous drug resistance, which occurs in untreated 
patients [17]. 
1.2.3.2 Cellular component 
Bone marrow stromal cells  
The BMSCs are essential for both normal plasma cells and MM plasma cells. 
However, differences are seen between normal BMSCs and MM BMSCs; for instance 
MM BMSCs produce high amounts of pro-inflammatory cytokines that stimulate MM 
growth. One explanation of the differences is that the MM cells select the population of 
BMSCs that best support the malignant cells [17]. BMSCs and MM cells interact through 
adhesion molecules leading to the production and secretion of MM-stimulating molecules 
such as interleukin 6 (IL-6) which stimulate MM cell growth, survival, drug resistance and 
migration [12,17]. 
Osteoclasts and osteoblasts 
Bone lesions are common in MM patients. This is the result of an increased osteolysis 
(mediated by osteoclasts) and decreased osteogenesis (mediated by osteoblasts).  
The MM BMSCs stimulate the osteoclastogenesis mainly through the expression of the 
receptor activator of nuclear factor kappa B ligand (RANKL) [12,15,17]. In normal BM, 
osteoprotegerin (OPG), secreted by osteoblasts and BMSCs, inhibits the maturation and 
activation of osteoclasts, thus protecting the bone against inadequate osteoclast activation.  
However, in MM BM the expression of OPG is downregulated [12,17]. 
In healthy individuals, bone resorption is followed by increased bone formation by 
osteoblasts, thus preventing the formation of osteolytic lesions. In MM, the activity and 
number of osteoblasts is decreased due to several factors including dysregulation of 
signalling molecules [12,15]. 
Endothelial cells 
The MM cells stimulate the endothelial cells in the BM to proliferate and to form 
microvessels leading to an increased angiogenesis which is especially notable in patients with 
active disease [12,15,17]. Thus, the availability of nutrients and oxygen as well as the 
removal of catabolites increase [12,17]. The endothelial cells also support the growth and 
progression of MM by secreting growth and invasive factors [12,17]. 
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Other cells 
Adipocytes seem to be important for proliferation and migration of MM cells in the initial 
stage of the disease, but as the disease progresses the adipocytes disappear from the BM [17]. 
Among the hematopoietic cells, macrophages have been shown to protect the cells from 
apoptosis. They also seem to support survival and stimulate proliferation of MM cells in vitro 
due to their secretion of IL-6 and vascular endothelial growth factor (VEGF). Eosinophils are 
another example of hematopoietic cells that stimulate proliferation through a contact-
independent manner [15]. 
1.2.4 Signalling pathways 
Several signalling pathways are involved in myeloma proliferation, survival, drug resistance 
and migration, Figure 3. The signalling pathways are activated by cytokines secreted from 
both MM cells and BMSCs. Anti-apoptotic proteins, cytokines and cell-cycle modulators are 
some of their downstream targets [18,19]. 
Activation of the nuclear factor κB (NF-κB) pathway results in upregulation of adhesion 
molecules and increased secretion of cytokines that influence MM cell growth, survival and 
migration [18]. In at least half of the MM patients the NF-κB pathway is constitutively active 
in both plasma cells and the BMSCs [19]. 
The mitogen-activated protein kinase (MAPK) pathway also influences cell differentiation, 
proliferation and survival. It is activated by RAS which are membrane-associated GTPases. 
NRAS and KRAS, two members of the RAS-family, are often mutated in MM and the 
mutation rate increases with disease progression. However, RAS mutations are rare in 
monoclonal gammopathy of undetermined significance (MGUS) and therefore RAS 
mutations are believed to be important for progression of MGUS to MM [18-20]. 
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is 
constitutively activated in 50% of the MM patients leading to decreased apoptosis [19,20]. 
The phosphatidylinositol-3 kinase (PI3K) pathway is activated in about half of the MM cases, 
but mutations of the pathway are unusual. Via downstream targets such as mTOR, the 
pathway affects cell proliferation and survival [19,20]. 
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Figure 3 Interaction of multiple myeloma cells with the bone marrow environment. ERK, extracellular signal-
regulated kinase; IGF1, insulin-like growth factor 1; IAPs, inhibitor of apoptosis proteins; MCL1, myeloid cell 
leukaemia sequence 1; ICAM1, intercellular adhesion molecule 1; VCAM1, vascular cell adhesion molecule 1; bFGF, 
basic fibroblast growth factor; HGF, hepatocyte growth factor; MIP1α, macrophage inflammatory protein-1α. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer [18], copyright 2007. 
1.2.5 Genetic alterations 
Chromosomal aberrations are common in MM and disease progression is probably the result 
of clonal evolution with accumulation of genetic alterations [21] [19]. Furthermore, studies 
have demonstrated the presence of several subclones with different chromosomal aberrations 
within the same patient. The subclones develop early in the disease process and are believed 
to be responsible for relapse [19,21,22]. 
The chromosomal aberrations can be divided into primary and secondary events. The primary 
events are important for plasma cell immortality and occur early in the evolution of the 
disease, as early as the MGUS stage [19,23]. The secondary events on the other hand are 
more common in smouldering MM, MM and plasma cell leukaemia and these events drive 
disease progression [19]. These secondary events are found only in subclones of the plasma 
cells and include secondary translocations, copy number variations, loss of heterozygosity, 
acquired mutations and epigenetic modifications [19,22]. 
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Homing and adhesion of multiple myeloma cells to the 
bone marrow. The homing of multiple myeloma cells 
to the bone marrow is mediated by the chemokine 
SDF1α, which interacts with its receptor CXCR4 on 
multiple myeloma cells. SDF1α induces motility, inter-
nalization of CXCR4, and cytoskeletal rearrangement 
in multiple myeloma cells; conversely, specific CXCR4 
inhibitors and anti-CXCR4 antibodies inhibit migra-
tion of multiple myeloma cells in vitro, suggesting that 
the SDF1α–CXCR4 interaction is a crucial regulator of 
Figure 1 | Interaction of multiple myeloma cells in their bone marrow milieu. Adhesion of multiple myeloma cells 
to bone marrow stromal cells (BMSCs) triggers cytokine-mediated tumour cell growth, survival, drug resistance and 
migration. Multiple myeloma (MM) cell binding to BMSCs upregulates cytokine secretion from both BMSCs and 
tumour cells. These cytokines activate major signalling pathways: extracellular signal-regulated kinase (ERK); Janus 
kinase 2 (JAK2)–signal transducer and activator of transcription 3 (STAT3); phosphatidylinositol 3-kinase (PI3K)–Akt; 
and/or nuclear factor κB (NFκB). Their downstream targets include: cytokines, such as interleukin 6 (IL6), insulin-like 
growth factor 1 (IGF1) and vascular endothelial growth factor (VEGF); anti-apoptotic proteins, such as BCL-X L, 
inhibitor of apoptosis proteins (IAPs), myeloid cell leukaemia sequence 1 (MCL1); and cell-cycle modulators (cyclin D). 
Adhesion-mediated activation of NFκB upregulates adhesion molecules such as intercellular adhesion molecule 1 
(ICAM1) and vascular cell adhesion molecule 1 (VCAM1) on both multiple myeloma cells and BMSCs, thereby further 
increasing the binding of multiple myeloma cells to BMSCs (the green boxes in the BMSC nucleus represent NFκB 
binding sequences in the promoter region of a target gene). Secretion of angiogenic factors, such as VEGF,  basic 
fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF), from multiple myeloma cells and BMSCs 
stimulates neo-angiogenesis. Receptor activator of NFκB ligand (RANKL) produced by BMSCs, and macrophage 
inflammatory protein-1α (MIP1α) produced by multiple myeloma c lls, stimulate ost oclastogenesi . By contrast, 
osteoprotegerin (OPG) secreted from osteoblasts and BMSCs inhibits osteoclastogenesis. Osteoblastogenesis is 
inhibited by multiple myeloma cells through the secretion of IL3 and Dickkopf 1 (DKK1) from multiple myeloma cells 
and HGF from BMSCs. Stimulation of osteoclastogenesis and inhibition of osteoblastogenesis promote osteolysis. 
This figure is modified with permission from REF. 72    ( 2003) American Society of Hematology. BMECs, bone marrow 
endothelial cells; CAMDR, cell adhesion-mediated drug resistance.
REVIEWS
588 | AUGUST 2007 | VOLUME 7  www.nature.com/reviews/cancer
© 2007  Nature Publishing Group 
  7 
According to the primary event, MM can be divided into hyperdiploidy and 
nonhyperdiploidy MM. Hyperdiploidy with trisomies involving the odd-numbered 
chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 can be found in 50–60% of newly diagnosed MM. 
Patients with a hyperdiploid karyotype seem to have a better prognosis [12,19,22,23]. 
Nonhyperdiploidy is detected in 40–50% of MM. It is characterized by translocations 
involving the immunoglobulin heavy (IGH) alleles at 14q32 and these translocations can be 
found in almost all of the plasma cells. IGH are strong enhancers causing overexpression of 
the partner chromosome, most often an oncogene [12,19,22,23].  
1.2.5.1 Translocations 
t(11;14) is the most frequent translocation, found in 15–20% of the patients. 
The translocation results in the overexpression of cyclin D1 and the prognostic impact is 
neutral or favourable [12,19,22-24]. 
t(4;14) has a negative impact on prognosis and is observed in approximately 15% of the MM 
patients making it the second most common IGH translocation [12,19,22,23]. 
The translocation upregulates two oncogenes, the fibroblast growth factor receptor 3 gene 
(FGFR3) and the multiple myeloma SET domain protein (MMSET). The latter of these two 
genes seems to be the most important molecular target for the translocation because FGFR3 
is upregulated in only about 70% of patients with t(4;14) [12,22,24]. 
t(6; 14) is found in only a few per cent of the MM patients. It increases the expression of 
cyclin D3 but does not seem to have an impact on prognosis [12,19,22,23]. 
t(14;16) is observed in 5–10% of the MM patients and causes the dysregulation of the MAF 
oncogene and is associated with aggressive disease [12,19,22,23]. 
t(14;20) also results in the upregulation of the MAF oncogene but this translocation is found 
in only about 1–2% of the patients [12,19,22,23]. It is associated with poor prognosis in MM 
[23]. However, in MGUS and smouldering MM the translocation is linked to long-term stable 
disease [19]. 
1.2.5.2 Chromosomal gains and losses 
Gain of 1q is associated with poor prognosis. It is observed in approximately 30–40% of the 
patients at diagnosis and in a greater portion of the patients at relapse, whilst it is uncommon 
in MGUS [19,22,23]. It is a marker of poor prognosis irrespectively of given treatment 
[12,19,23]. 
Loss of 1p is also linked to poor prognosis and is found in about 30% of patients with MM 
[12,19,23]. 
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Loss of chromosome 13/13q, found in 50% of myeloma cases, was previously thought to be 
a marker of poor prognosis. However, later studies have demonstrated that del(13/13q) is not 
an independent prognostic factor and that the adverse prognosis is dependent on the 
correlation to other high-risk lesions [19,23]. 
Loss of 17p is linked to an aggressive disease with low overall survival (OS). It is identified 
in 10% of newly diagnosed myeloma cases and becomes more frequent in later stages of the 
disease. Loss of 17p results in a lower expression of the tumour suppressor gene TP53 which 
can explain the poor prognosis [19,23,25]. Mutated TP53, which is also associated with poor 
prognosis, is seen in a lower frequency among MM patients [19]. 
1.2.5.3 8p21 
Dysregulations originating from changes in the 8p21 region have been linked to various 
malignancies including leukaemic mantle cell lymphoma [26] and B cell lymphoma [27], 
as well as to prostate cancer [28]. Del(8)(p21) is an independent predictor of poor prognosis 
in MM, and both progression free survival (PFS) and OS are adversely affected [29]. 
In Paper IV, we examine the consequences of del(8)(p21) with regards to treatment response 
and bortezomib resistance. Therefore, del(8)(p21) is discussed in more detail in later chapters.  
1.3  EPIDEMIOLOGY 
The incidence of MM increases with age and in Sweden the median age at diagnosis is 
70 years for men and 73 years for women [30]. Worldwide, the incidence of MM is estimated 
at 86 000 cases per year [31] and in Sweden approximately 623 patients were diagnosed 
yearly between 2008 and 2011, which translates into an age-adjusted incidence rate of 
6.5/100 000 [30]. The corresponding incidence rate in the USA is 6.3/100 000 [32]. 
The disease is more common among African Americans [32,33] and slightly more men than 
women are diagnosed with MM; in Sweden 56% of the 2 494 patients that were diagnosed 
between 2008 and 2011 were men. The difference is due to a higher incidence of MM in men 
younger than 75 years, whilst no difference is seen between men and women over the age of 
75. However, the age-specific incidence rate is higher for men in all age groups with the 
highest rate among those aged 80–84 years (45 men per 100 000 compared to 30 women per 
100 000) [30]. 
MGUS, a premalignant stage that precedes MM [34], is found in 1% of adults older than 
25 years [12] and in 3–4% of adults over 50 years [35]. The risk of progression from MGUS 
to MM is 0.5–1% per year. The risk of progression is much higher for patients with the 
intermediate clinical stage called smouldering MM. The rate of progression in this group is 
10% each year for the first 5 years. However, the prognosis for patients with smouldering 
MM varies; some develop end organ damage within two years whilst others have a very low 
rate of progression [35].  
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1.4 SYMPTOMS AND DIAGNOSIS 
Common symptoms and clinical features of MM are bone pain (due to lytic bone lesions), 
infections, weakness, anaemia, weight loss, hypercalcemia and renal impairment [36].  
The most common clinical features at diagnosis are shown in Table I [30]. However, 
in 10–40% of the patients the disease is diagnosed before symptoms appear [36]. 
These patients are classified as having smouldering MM [35].  
 
Table I. The most common clinical features at diagnosis and the proportion of patients in Sweden with each feature. 
Clinical feature 
Proportion of  
patients (%) 
Skeletal disease 
Osteolytic lesions 
Vertebral compression fractures 
76 
61 
15 
Anaemia 33 
Renal failure 18 
Hypercalcemia 15 
 
1.4.1 Lytic bone lesions and hypercalcemia 
Bone pain, a presenting symptom in 40–70% of the patients, is attributable to osteolytic 
destruction and pathological fractures. The osteolysis also leads to an increased release of 
calcium resulting in hypercalcemia, which can be further aggravated by renal dysfunction. 
The symptoms of hypercalcemia depend on the serum calcium level and on how fast the 
calcium level has risen. Patients with mild to moderate hypercalcemia (serum calcium  
>2.6–3.1 mmol/L) can demonstrate thirst, polyuria, nausea, muscular weakness, constipation 
and malaise. As the serum calcium increases, headache, confusion and dehydration can also 
appear and in the most severe cases acute renal failure, cardiac ventricular arrhythmia, 
shortening of the QT interval, coma and death may follow [36-38]. 
1.4.2 Infections 
Bacterial infections are common among MM patients and infections are seen in 10–20% of 
the patients at diagnosis. It becomes more frequent in later disease and 15–60% of MM 
deaths are due to infections. MM patients have an impaired immune defence due to disease-
induced immune defects (mainly because of low concentrations of polyclonal 
immunoglobulins). The susceptibility to infection is further increased by the 
immunosuppression caused by MM treatment. The respiratory tract is the most common site 
of infection and Streptococcus pneumonia and Haemophilus influenza are the most 
frequently found pathogens in non-neutropenic patients, whereas Staphylococcus aureus and 
Gram-negative bacteria are more common among neutropenic patients [36,37]. 
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1.4.3 Anaemia 
Anaemia is a rather common finding at diagnosis (20–60%), whilst significant 
thrombocytopenia and neutropenia are rare. There is also a correlation between disease stage 
and anaemia  [36,37]. Factors such as lack of erythropoietin due to renal insufficiency, 
too few erythrocyte precursor cells, and impaired iron utilization cause anaemia either 
separately or combined. Furthermore, MM treatment can also contribute to anaemia [37].  
1.4.4 Renal impairment 
Renal impairment is a common finding in MM patients and has been associated with poor 
prognosis. Monoclonal light chains that are deposited in the renal tubules are the main cause 
of kidney damage. Although there are other factors that also cause renal failure in 
MM patients such as hypercalcemia, dehydration, infections and nephrotoxic drugs 
[36,37,39-41], only renal impairment caused by light chain cast nephropathy is considered a 
myeloma defining event according to a clarification from the International Myeloma 
Working Group (IMWG) [35].  
Previously, the definition of renal impairment was a serum creatinine >173 µmol/L [42]. 
According to this definition almost 20% of MM patients in Sweden suffer from renal 
impairment at diagnosis. Additionally, 35% have a serum creatinine >110 µmol/L [30]. 
However, serum creatinine is not a true reflection of renal function. Therefore, in recently 
updated criteria IMWG recommend that glomerular filtration rate (GFR) should be used for 
assessing renal function. The GFR rate can either be measured or estimated using the 
modification of diet in renal disease (MDRD) formula or the chronic kidney disease 
epidemiology collaboration (CKD-EPI) formula and renal impairment is defined as 
GFR <40 mL/min [35]. 
1.4.5 Diagnostic criteria and staging 
The diagnostic criteria according to the IMWG can be seen in Table II and Table III [35]. 
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Table II. The diagnostic criteria according to International Myeloma Working Group. 
Monoclonal gammopathy of undetermined significance 
• Serum M protein <30 g/L  
• Clonal bone marrow plasma cells <10% 
• Absence of myleoma defining events and amyloidosis 
Smouldering multiple myeloma 
• Serum M protein (IgA or IgG) ≥30 g/L or urinary M protein ≥500 mg/24 h  
and/or clonal bone marrow plasma cells 10–60% 
• Absence of myeloma defining events and amyloidosis 
Multiple myeloma 
• Clonal bone marror plasma cells ≥10% or biopsy-proven plasmacytoma 
• ≥1 myeloma defining event 
 
Table III. Myeloma defining events.  
End organ damage Biological markers of malignancy 
• Hypercalcaemia: Serum calcium >0.25 mmol/L above 
normal or >2.75 mmol/L 
• Renal insufficiency: Creatinine clearance <40 mL/min 
or serum creatinine >177 µmol/L 
• Anaemia: Haemoglobin >20 g/L below normal or 
haemoglobin <100 g/L 
• Bone lesions: ≥1 osteolytic lesions on skeletal x-ray, 
CT or PET-CT 
• Clonal bone marrow plasma cells ≥60% 
• Serum free light chain ratio ≥100 
• >1 focal lesions on MRI 
CT, computed tomography; PET-CT, positron emission tomography-computed tomography; MRI, magnetic resonance 
imaging. 
 
1.4.5.1 Staging 
Several staging systems have been used over time, but the current standard is the 
International Staging System (ISS), Table IV. This staging system was published in 2005 
based on data from over 10 000 patients in North America, Europe and Asia [43] and has 
been validated in a European study [44,45]. 
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Table IV. International Staging System. 
Stage Criteria 
Median survival 
(months) 
I β2-microglobulin <3.5 mg/L 
and 
Serum albumin ≥3.5 g/dL 
62 
II β2-microglobulin <3.5 mg/L and serum albumin <3.5 g/dL 
or 
β2-microglobulin 3.5–5.4 mg/L irrespective of serum albumin level 
44 
III β2-microglobulin ≥5.5 mg/L 29 
 
1.5 TREATMENT 
There has been a huge increase in available treatments during the last fifteen to twenty years, 
as depicted in Figure 4. However, not all MM patients receive treatment since it is not 
initiated until the patient becomes symptomatic. This was previously defined as the presence 
of  one or more of the so called CRAB criteria which comprise hyperCalcemia, Renal 
insufficiency, Anaemia and Bone lesion [42]. In the latest update from IMWG, the definition 
of disease demanding treatment has been expanded and now also involves MM defining 
events and biomarkers of malignancy, Table III [35]. 
 
Figure 4. The development of myeloma treatments. 
When treatment is initiated the choice of regimen is dependent on whether or not the patient 
is eligible for HDT. Patients with a biological age under 70 are usually candidates for HDT 
whilst those who are older or have extensive comorbidity are not. Before HDT, 
the patient receives induction treatment for 3–4 cycles in order to decrease the tumour 
burden. The current Swedish treatment recommendations  are summarized in Table V and 
Table VI. 
1999  
First report on 
thalidomide 
April 2004  
Bortezomib EU licence 
April 2005  
Bortezomib approved  
for first relapse in Europe 
2007  
MPV Phase III trials 
and  
Bortezomib front-line trials 
2007  
Lenalidomide + 
dexamethasone approved 
for first relapse in Europe 
1958 
Melphalan 
1980s 
Myeloablation  
+  
ASCT or AlloSCT 
1990s  
Supportive care 
1969 
Prednisone  
+ melphalan 
1995 
Tandem ASCT 
2006  
MPT Phase III 
trials 
2014 
Pomalidomide 
2015 
Carfilzomib 
2015 
Panobinostat 
1962 
Prednisone 
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Table V. Initial treatment for HDT eligible patients.  
Regimen Interval Studies 
VCD 
• Bortezomib 1.3 mg/m2 subcutaneous days 1, 4, 8 and 11  
• Cyclophosphamide 1000 mg/m2 intravenous day 1 
• Dexamethasone 20 mg orally, days 1-2, 4-5, 8-9 and 11-12 
 3 weeks Bensinger et al. 2009 [46] 
Reeder et al. 2009 and 
2010 [47,48] 
Kumar et al 2012 [49] 
VTD 
• Bortezomib 1.3 mg/m2 subcutaneous days 1, 4, 8 and 11 
• Thalidomide 50–200 mg orally, daily 
• Dexamethasone 20 mg orally, days 1-2, 4-5, 8-9 and 11-12 
3 weeks Cavo et al. 2010 [50] 
Rosiñol et al. 2010 and 
2012 [51,52] 
Moreau et al. 2011 
Ludwig et al 2012 and 
2015 [53,54] 
CTD 
• Cyclophosphamide 500 mg orally, days 1, 8 and 15 
• Thalidomide 100–200 mg orally, daily 
• Dexamethasone 40 mg orally, days 1-4 and 15-18 
4 weeks Yang et al. 2010 [55] 
Morgan et al. 2012 [56] 
 
 
Table VI. Initial treatment for non-HDT eligible patients.  
Regimen Interval 
MPT 
• Melphalan 0.25 mg/kg body weight, orally days 1-4 
• Prednisolone 2 mg/kg body weight orally days 1-4 
• Thalidomide 50–100 mg orally daily 
4-6 weeks 
MPV 
• Melphalan 0.18 mg/kg body weight orally days 1-4 
• Prednisolone 2 mg/kg body weight orally days 1-4 
• Bortezomib 1.3 mg/m2 subcutaneous once weekly for 4 weeks 
5 weeks 
VTD 
• Bortezomib 1.3 mg/m2 subcutaneous days 1, 4, 8 and 11 
• Thalidomide 50–200 mg orally, daily 
• Dexamethasone 20 mg orally, days 1-2, 4-5, 8-9 and 11-12  
3 weeks 
CTD 
• Cyclophosphamide 500 mg orally, days 1, 8 and 15 
• Thalidomide 100–200 mg orally, daily 
• Dexamethasone 40 mg orally, days 1-4 and 15-18 
4 weeks 
Vel-Dex twice weekly 
• Bortezomib 1.3 mg/m2 subcutaneous days 1, 4, 8 and 11 
• Dexamethasone 20 mg orally days 1-2, 4-5, 8-9 and 11-12 
3 weeks 
Vel-Dex once weekly 
• Bortezomib 1.3 mg/m2 subcutaneous days 1, 8, 15, 22 
• Dexamethasone 20 mg orally days 1-2, 8-9, 15-16, 22-23 
5 weeks 
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1.5.1 Chemotherapy and corticosteroids 
1.5.1.1 Alkylating agents 
The alkylating agents cause cross-linkage of DNA strands by alkylation of DNA nucleotides, 
thereby inhibiting DNA replication. 
Melphalan was introduced as MM treatment in the late 1950s and a decade later it was 
combined with prednisone with positive results; the combination of oral melphalan and 
prednisone (MP) resulted in a prolonged survival of 6 months when compared to melphalan 
as single treatment [57-62]. The combination MP was for many years the standard therapy for 
patients not eligible for HDT [63]. The most common side effect of melphalan is 
myelosuppression, especially thrombocytopenia, but it is otherwise well tolerated [60]. 
However, melphalan is partly eliminated via the kidneys and therefore dose adjustment is 
necessary in patients with renal impairment [64-67]. 
Cyclophosphamide can, like melphalan, be administered orally or intravenously. Studies 
have revealed that it is as effective as melphalan and that it also has an effect in melphalan-
resistant patients [68-74]. The combination of cyclophosphamide and prednisolone has also 
been proven to be effective in late stages of the disease [75-77]. As for melphalan, 
myelosuppression is the dose-limiting toxicity, but neutrophils are more affected than 
thrombocytes [60]. In patients with severe renal insufficiency, the dose needs to be adjusted 
because even though the drug is metabolised in the liver, active metabolites are excreted via 
the kidneys [78]. 
Bendamustine is another alkylating agent. However, it differs from both melphalan and 
cyclophosphamide because it is also a purine analogue [79]. It was synthesized in East 
Germany as early as the 1960s [80], but it was not until the German reunification that it 
became available in other countries. However, at that time there was a lack of scientific 
evidence confirming its effect and therefore several clinical trials were initiated [81]. 
In Europe bendamustine was approved as upfront treatment for older MM patients in 2010 
following a randomized trial comparing bendamustine plus prednisolone to MP. The study 
demonstrated equal overall response rates for the two therapies, but a higher rate of complete 
response (CR) as well as a longer time to treatment failure [82]. There are also several studies 
indicating an effect in relapse/refractory MM (RRMM) both with and without steroids [83] as 
well as in combination with novel agents [84-92]. Bendamustine also seems to be effective 
and well tolerated in patients with renal impairment [93-95]. 
Combinations 
Several alkylator-based combinations have been studied and when compared to MP the 
response rate was found to be higher for many of the combinations [96-101]. 
However, other studies reported that there was no difference in survival in comparison to MP 
[102,103] and two meta-analyses determined that there was no significant survival benefit for 
combination chemotherapy in comparison to MP [104,105]. 
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1.5.1.2 Other cytotoxic agents 
Other cytotoxic agents worth mentioning are vincristine and doxorubicin. Vincristine belongs 
to the group of vinca alkaloids, whilst doxorubicin is an anthracycline. The vinca alkaloids’ 
antitumour function is due to inhibition of mitosis [106,107], and the anthracylcines inhibit 
DNA, RNA and protein synthesis by binding to DNA-associated enzymes [108]. 
In the beginning of 1980s, the combination of vincristine, doxorubicin and dexamethasone 
(VAD) was shown to be effective in patients refractory to alkylating agents [109,110] and 
was for many years the standard induction therapy for patients eligible for HDT. However, 
the combination is no longer in use since it has been replaced by new and better treatment. 
1.5.1.3 Glucocorticoids 
There are a few different glucocorticoids that are being used in MM treatment: prednisone, 
prednisolone, dexamethasone and betamethasone. Prednisone was introduced in the 1960s 
when studies of prednisone as single agent could demonstrate an effect on the M protein level 
and on anaemia, but not on survival [111]. It is uncertain whether steroids in conventional 
doses have any effect on MM. However, high-doses of dexamethasone have been found to 
give a rapid response [109,112,113].  
1.5.2 Novel agents 
Until the late 1990s, MP was the standard treatment but in 1999 a major progress was seen 
with the introduction of the first novel agent, thalidomide. 
1.5.2.1 Immunomodulatory drugs 
The immunomodulatory drugs (IMiDs) function in various ways; they inhibit for instance the 
proliferation of malignant cells and they disrupt the interaction between myeloma cells and 
their environment. Furthermore, as the name suggests the IMiDs also affect the immune 
system with activation of T cells and NK cells [114]. 
Thalidomide was originally developed in the 1950s and sold as a sedative until the beginning 
of 1960s when it was withdrawn due to its severe teratogenic side effect [62,115]. 
In the late 1990s, it was tested on five MM patients with end-stage disease. One of the 
patients achieved a near complete response and a clinical trial was launched in which 30% of 
the patients, who all had advanced MM, responded [116]. When combined with 
dexamethasone the response rate in patients with RRMM increased to approximately 50% 
[117-125]. Furthermore, there are reports that thalidomide is effective in MM patients with 
involvement of the central nervous system [126]. The most common side effect of 
thalidomide is constipation, weakness and somnolence [116], but in combination with high-
dose dexamethasone there is also an increased risk of venous thrombosis [125,127]. The 
elimination of thalidomide is not dependent on renal function and there is therefore no need 
for dose adjustment in patients with renal impairment [128]. 
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Lenalidomide is an analogue of thalidomide that was approved in the USA in 2006 for the 
treatment of RRMM [129,130]. When it was combined with dexamethasone 90% of newly 
diagnosed patients responded [131] and the combination showed superior response in RRMM 
compared to dexamethasone alone [132,133]. The most frequent side effects are neutropenia, 
thrombocytopenia and venous thrombosis [132]. Lenalidomide is partly eliminated in urine 
and it is therefore necessary to adjust the dose depending on renal function [134].  
Pomalidomide is a newer analogue of thalidomide. Studies have demonstrated the 
effectiveness of pomalidomide in RRMM patients both as a single agent [135,136] and in 
combination with low-dose dexamethasone, even in patients refractory to other IMiDs and/or 
bortezomib [137-140]. A phase III study compared pomalidomide plus low-dexamethasone 
to high-dose dexamethasone and found a longer PFS and a better response rate in the 
pomalidomide group [141]. The pharmacokinetics of pomalidomide does not seem to be 
affected by renal impairment, suggesting that it can be administered in full approved dose in 
patients with kidney failure [142]. 
1.5.2.2 Proteasome inhibitors  
The proteasomes are important for the intracellular degradation of several proteins of which 
some are involved in the regulation of physiological and/or pathophysiological processes. 
In several cancers the proteasome pathway is important for the growth and spread of the 
malignant cells. Malignant cells often have an increased proteasome activity and the 
inhibition leads to growth arrest and apoptosis [143]. 
Bortezomib became available shortly after its efficacy in patients with RRMM was 
demonstrated in 2003 and 2004 in two phase II trials (SUMMIT and CREST) [144-146]. 
These studies were followed by a phase III trial comparing bortezomib to high-dose 
dexamethasone (the APEX trial) [147,148]. The studies demonstrated that bortezomib was 
effective as single agent in patients with RRMM, showing a response rate (partial response 
(PR) and CR) of 27–43%. Similar response rates were seen when using single-agent 
bortezomib as frontline treatment [149,150]. Bortezomib has also been shown to be effective 
in combination with various other agents, both in frontline and in later lines of treatment. 
For instance, when it was combined with dexamethasone 67–90% of newly diagnosed 
patients responded [151-154]. The VISTA trial examined the effect of adding bortezomib to 
MP for non-HDT eligible patients and could demonstrate a clear survival benefit with this 
combination compared to MP [155-157]. Peripheral neuropathy is an important dose-limiting 
side effect. However, a study in 2011 showed that administrating bortezomib subcutaneously 
was just as effective as intravenous treatment, but with a lower incidence of peripheral 
neuropathy and since then subcutaneous treatment is preferred [158]. There is also a risk of 
herpes zoster infection due to reactivation of the virus. Therefore, prophylaxis should be 
prescribed during bortezomib treatment. Other common side effects include 
thrombocytopenia and neutropenia [159,160]. Bortezomib is a good alternative in patients 
with renal impairment as no dose adjustment is necessary in these patients [161,162]. 
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Carfilzomib is a newer proteasome inhibitor and is expected to be approved in Sweden later 
this year for RRMM. The first reports from a phase II trials demonstrated a response rate of 
24% and OS of 15.6 months in a group of heavily pre-treated patients of which the majority 
were refractory to bortezomib [163]. In bortezomib-naïve patients with RRMM response 
rates varied between 42 and 52% depending on dosage. Neither median duration of response 
nor  time to progression (TTP) was reached for those patients who received the higher doses 
[164]. Phase III trials are being conducted and the preliminary results indicate high response 
rates using a combination of carfilzomib and low-dose dexamethasone [165] and both good 
response and improved PFS when carfilzomib was added to lenalidomide and dexamethasone 
[166]. 
Ixazomib is an oral proteasome inhibitor that is under investigation. Preliminary data indicate 
effect in RRMM when used as a single agent, even in patients refractory to bortezomib 
[167,168]. Combined with lenalidomide and dexamethasone it has been studied as up-front 
treatment [169].  
1.5.3 High-dose treatment with stem cell support 
High-dose treatment (HDT) with melphalan followed by autologous stem cell transplantation 
(ASCT) has, since the late 1990s, been the standard treatment for patients under the age of 
65 years. The effect of HDT has been studied in several clinical trials of which the majority 
demonstrated an improved response rate and PFS [170-175] and three of the studies also 
found a better OS compared to conventional therapy [170,172,173]. Nowadays, patients often 
receive a second HDT at relapse, provided that they had a good response to their previous 
HDT [176]. 
Despite positive results and long-term outcomes that are probably better than for HDT [177-
179], the role of allogeneic stem cell transplantation is more controversial due to the high 
transplant-related mortality rate that is seen when using myeloablative conditioning. 
Reduced intensity non-myeloablative conditioning (RIC) decreases the transplant-related 
mortality [180]. However, the risk of late relapses increases after RIC transplantations [181]. 
1.5.4 Response evaluation 
Treatment response is evaluated according to IMWG criteria, Table VII, [182]. In the last few 
years, data has emerged showing the importance of checking for minimal residual disease 
(MRD) when a patient is in stringent complete response (sCR), since MRD-negative patients 
have a markedly better OS than MRD-positive patients [183,184]. However, the optimal 
method for detection of MRD in MM patients is not yet clear [185]. 
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Table VII. Response criteria. 
Response Serum M protein Urine M protein Bone marrow Other 
Stringent complete response 
(sCR) 
Undetectable by 
immunofixation 
Undetectable by 
immunofixation 
Absence of 
clonal cells 
Normal free 
light chain 
ratio 
Complete response (CR) Undetectable by 
immunofixation 
Undetectable by 
immunofixation 
≤5% plasma 
cells 
 
Very good partial response 
(VGPR) 
≥90% reduction <100mg/24 hours   
Partial response (PR) ≥50% reduction <200mg/24 hours   
No response (NR) <50% reduction    
Progressive disease (PD) 25% increase 
Absolute increases of  
≥5 g/L 
25% increase 
≥200 mg/24 hours 
  
 
1.6 PROGNOSIS 
There is a large variation in duration of survival among individual MM patients, some only 
surviving a few months, whilst others live for many years [46]. However, with the 
development of new treatments the survival has gradually increased. In Sweden, 
the 1-year survival rate has increased each decade between 1973 and 2003 and for patients 
younger than 60–70 years the 5-year and 10-year survival rates have also increased [47]. 
Most likely, the improved survival rates seen since the 1980s are largely due to the 
introduction of HDT followed by ASCT. This was demonstrated in a Nordic population-
based study in which the survival rate among HDT patients was compared to that of a 
historical control. The median OS for the historical control was found to be 3.7 whilst the 
median OS of the HDT had not been reached at the end of the study and the difference was 
found to be significant [48]. Nevertheless, since the introduction of novel agents the OS has 
increased even more [49-51]. For instance, the median OS among HDT patients relapsing 
before the introduction of novel agent was found to be 2.7 years whilst those relapsing when 
novel agents were available had a median OS of 6 years and a post relapse survival of 
1.3 years and 3.6 years respectively [52]. 
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2 AIMS 
Multiple myeloma is an incurable disease and the majority of patients receive several 
treatment lines during the course of the disease. In the last decades, many new treatment 
alternatives have emerged and the treating physician now has numerous treatments to choose 
from. These different treatment options have been well studied in clinical trials. However, 
clinical studies focus on a specific treatment in a specific line of treatment and there is very 
little data on the effectiveness of re-treatment or on the survival as a function of the entire 
treatment sequence. 
Beside treatment, there are other factors that predict survival in MM, including 
beta-2-microglobulin, creatinine, haemoglobin, calcium, bone lesions as well as various 
chromosomal aberrations. However, in the era of novel treatment the impact of these factors 
on survival is not fully understood. 
Therefore, the aims of this thesis were: 
 
1. To achieve a better understanding of the order in which the treatments should be 
given. 
 
2. To define factors affecting prognosis. 
 
3. To increase the knowledge of cytogenetic abnormalities and their influence on 
prognosis and choice of treatment, with special focus on del(8)(p21) and bortezomib 
treatment. 
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3 MATERIALS AND METHODS 
3.1 STUDY POPULATION 
3.1.1 Paper I, II and III 
In Paper I, HDT eligible patients were studied whilst Papers II and III included newly 
diagnosed patients demanding treatment. Data including age, sex, type of myeloma and 
extent of bone disease as well as laboratory measurements at diagnosis were collected 
retrospectively from the hospitals’ electronic medical records. Serum M protein and urine 
M protein values were collected at baseline and every significant change in the M protein 
level was noted. For Papers II and III, the MM drugs given in each treatment line were 
noted, with specific start and stop dates for each drug or drug combination. Paper III focused 
on MM patients with renal impairment at diagnosis, defined as eGFR <60 mL/min/1.73 m2.   
The patients were divided according to Figure 5, Figure 6 and Figure 7. 
3.1.2 Paper IV 
Bone marrow aspirates from newly diagnosed MM patients were collected and the 
CD138+ plasma cells from these samples were selected for further analysis.  
For 140 consecutive patients clinical data, including information about given treatment and 
response to treatment, were collected. The patients were divided according to Figure 8. 
3.2 DEFINITION OF ENDPOINTS 
In all papers, response to treatment was assessed according to IMWG criteria, Table VII 
[182]. However, there was one exception: we used the term near complete response (nCR) 
instead of CR, since the clinical practice did not require that an undetectable M protein be 
confirmed by immunofixation. 
In Papers I–III we used the terms:  
• Time to next treatment (TTNT): the time between the start date of the administered 
drugs in the current treatment line and the start date of the administered drugs in the 
next treatment line 
• Time to progression (TTP) or progression free survival (PFS): the time between the 
start date of the administered drugs in the current treatment line until progressive 
disease 
• Overall survival (OS): the time from start of treatment to death or last follow-up. 
For a portion of the patients in Paper III, renal response was also assessed according to the 
criteria suggested by Ludwig et al and the IMWG, Table VIII, [186,187]. 
 
 22 
Table VIII. Definition of renal response.  
Renal response 
Baseline GFR  
(mL/min) 
Best GFR response  
(mL/min) 
Complete response 
(CRrenal) 
<50 ≥60  
Partial response (PRrenal) <15 30-59 
Minimal response (MRrenal) <15 
15-29 
15-29 
30-59 
3.3 LABORATORY METHODS 
3.3.1 Fluorescent in situ hybridization 
Fluorescent in situ hybridization (FISH) can be  used to detect chromosomal abnormalities. 
It utilises specific probes that are labelled with fluorochrome and bind to single-stranded 
DNA and can thus identify either a specific or multiple chromosomal structures or a unique 
DNA sequence. The bound probes are then visualized by fluorescence microscopy [188]. 
In Paper III, FISH with a 13q14.3 deletion probe was performed on CD138+ BM cells. 
Normal peripheral blood mononuclear cells from donor were used as control.  
FISH analysis was also performed in Paper IV to find other chromosomal abnormalities in 
addition to del(8)(p21), that are commonly seen in MM patients.  
3.3.2 Real-time polymerase chain reaction 
Polymerase chain reaction (PCR) makes it possible to detect small amounts of DNA in a 
sample by amplifying it. In standard PCR the reaction product is not detected until the end of 
the reaction, whilst in real time PCR the product is detected as it is amplified [189]. 
In Paper IV, quantitative real-time PCR was used to identify differences in gene expression 
levels between patients with and without del(8)(p21). The mRNA levels of genes located on 
the 8p21 region as well as of genes with a functional link to genes located in this region were 
measured. 
3.3.3 Flow cytometry 
Flow cytometry is a method to identify and characterize different cell types within a 
population. In the flow cytometer one cell at a time passes a laser beam. Depending on the 
size of the cell and its cytoplasmic granularity the light will be scatter in different ways. 
Furthermore, specific molecules on the surface of the cells or inside the cells can be marked 
with fluorescently labelled antibodies and the emitted fluorescence can also be measured 
[190]. 
Flow cytometry was used in Paper IV to examine the changes in cell surface expression of 
tumour necrosis factor-related apoptosis inducing ligand (TRAIL) receptors due to in vitro 
bortezomib treatment. To study the receptor expression, CD138+ plasma cells and 
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CD138- BM mononuclear cells with and without del(8)(p21) were cultured in the presence or 
absence of bortezomib and stained with fluorescently labelled anti-TRAIL receptor 
antibodies, anti-CD38 and anti-CD138. The CD138- cells were also stained with anti-CD45 
before analysis.  
Flow cytometry was also used to assess the sensitivity of myeloma cells with and without 
del(8)(p21) to bortezomib and soluble TRAIL/APO2L. Plasma cells were cultured with or 
without bortezomib and incubated with soluble TRAIL/APO2L before they were stained with 
anti-CD138 and anti-CD38 antibodies followed by Annexin V and propidium iodide staining 
and the amount of viable, apoptotic and dead cells could then be measured. 
3.4 STATISTICAL METHODS 
In Papers I–III, descriptive statistics were used to characterize the data and Cox regression 
analyses were used to identify predictive factors. In all papers, life table curves were 
calculated according to Kaplan-Meier and compared using log-rank tests. 
In Paper II, multiple comparisons of continuous data were performed by analysis of 
variance, ANOVA. In the case of a statistically significant result in the ANOVA, statistical 
comparisons were made by use of the post-hoc test proposed by Fisher as a control for 
multiplicity. Paper II also employed multiple hypothesis testing. This means that each 
hypothesis was analysed separately and the existence of patterns in and the consistency of the 
results were considered in the analysis. In Paper III, the Mann-Whitney test for uncorrelated 
means was performed to investigate possible differences between two independent groups. 
In Paper IV, one-way ANOVA and paired/unpaired t-tests were used to analyse the relative 
expression of certain genes in MM cells with and without del(8)(p21). 
In all papers, a probability value (P) of <0.05 was considered as significant. 
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Figure 6. Patients in Paper II. 
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4 RESULTS AND DISCUSSION 
4.1 PROS AND CONS OF REAL-LIFE 
Treatment guidelines are mostly dependent on the results of randomized clinical trials or 
meta-analysis of these trials. However, the study population in prospective clinical trials 
usually consists of highly selected patients and does not necessarily reflect the group of 
patients that will receive the treatment. Furthermore, randomized clinical trials are designed 
to address specific questions, such as the effect of a specific drug or drug combination in the 
first or second line of treatment on response and/or survival. The question of response and 
survival in relation to entire treatment sequences is nearly impossible to answer in 
randomized clinical trials, since this would require such a large number of patients as well as 
a very long follow-up time. For these reasons it is necessary to conduct population-based 
studies that will give more and better information about overall outcome for all patients in a 
given population.  
In Papers I–III, we studied a large cohort of MM patients that were diagnosed and treated at 
up to 15 different hospitals in Sweden. The patients were obtained from the Swedish Cancer 
Registry, which covers almost 94% of all individuals with malignant disease [191]. 
In Paper I, we analysed response data from 88 patients treated with VCB and 129 patients 
treated with VAD or CyBet prior to HDT. Prior studies have demonstrated that combinations 
with novel agents lead to improved response rates and survival after HDT compared to 
conventional chemotherapy [154,192]. Therefore, we wanted to find out whether the positive 
results seen in clinical trials were also achieved in clinical reality. 
Inspired by encouraging results in Paper I, we continued to look at a larger population of 
MM patients (n=1638) (Papers II and III). These patients had been treated at different 
hospitals in Sweden, some at university hospitals and others at regional or local hospitals. 
We therefore believe that our population represents the full spectrum of different 
MM patients and that our results are representative for the whole Swedish MM population.  
One possible drawback with the study set-up is that we did not collect data on comorbidity. 
However, we tried to cover possible differences between the studied groups by adjusting for 
age, sex, type of MM and important laboratory values at diagnosis. Moreover, since the data 
were collected from different hospitals it is influenced by centre-specific clinical routines 
such as the intervals between response evaluation. Most often, response was measured every 
month, but sometimes 6–8 weeks passed between the controls. This might affect TTP and 
PFS, but to a lesser extent TTNT. Therefore, we believe that TTNT is more reliable in this 
setting. Furthermore, an undetectable M protein by standard electrophoresis was not always 
confirmed by immunofixation since it was not required in clinical practice. Consequently, 
the patients could not meet the criteria for CR. Therefore, we chose to analyse nCR instead. 
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4.2 TRICK OR TREAT? THE EXPERIENCE OF NOVEL DRUGS FOR NON-HDT 
PATIENTS 
In Paper II, we could confirm that the survival benefits with novel drugs, which have been 
demonstrated in clinical trials [155,156,193-199], are also seen in real life. Nevertheless, 
even though the OS in the elderly MM population is approaching the survival in a matched 
Swedish population, MM can still not be considered a chronic disease and therefore there is 
still room for improvement. 
Approximately two thirds of the patients in Paper II did not receive HDT. Patients treated 
with novel drugs were compared to those who received conventional treatment, Figure 6. 
Among non-HDT patients there were small, yet statistically significant differences in age, 
haemoglobin and albumin between those treated with novel drug and those treated with 
conventional ones, Table IX. However, the differences in laboratory values were small and of 
little clinical importance and as mentioned above we adjusted for these differences in 
multivariate analysis. 
Table IX. Population characteristics at diagnosis for patients in Paper I. 
   Non-HDT 
1st line treatment 
 HDT Non-HDT 
Novel 
agents 
Conventional  
agents  
P 
No. of patients 511 1127 323 780  
Male, % 63 51 50 55 0.117 
Median age at diagnosis,  
years (range) 
58 (32–71) 75 (35–97) 72 (41–90) 76 (35–97) <0.001 
Skeleton destruction, % 
0 
1 
More than 1 
 
24 
10 
66 
 
37 
9 
55 
 
36 
6 
58 
 
37 
9 
54 
 
 
0.206 
Laboratory values at  
diagnosis, median 
Creatinine, mmol/L 
Ca, mmol/L 
Β2µ, mg/L 
Hb, g/L 
Albumin, g/L 
 
 
86 
2.4 
3.1 
110 
35 
 
 
99 
2.4 
4.0 
107 
33 
 
 
95 
2.4 
3.9 
109 
34 
 
 
101 
2.4 
4.0 
106 
33 
 
 
0.102 
0.395 
0.535 
0.002 
0.032 
 
Patients not receiving HDT had a clear survival benefit from novel treatment. For these, 
upfront treatment with novel drugs led to a median OS of 4.9 years compared to 2.3 years for 
those treated with conventional chemotherapy (Figure 9A) and the survival benefit remained 
in the multivariate analysis. These results are in line with those seen in clinical trials 
[157,199,200]. Interestingly, patients treated with novel agents in both first and second line 
had not reached the median OS at the end of the study (Figure 9B), whilst patients receiving 
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conventional treatment in first line and novel drugs in second line had a median OS of 
3.3 years and patients receiving conventional treatment in both first and second line had a 
median OS of 3.0 years. This indicates that novel agents should be used upfront instead of 
being saved until relapse and that the survival can be prolonged with optimal use of existing 
drugs. 
We were also interested in finding out whether the recent development of MM treatments 
meant that the OS among MM patients would be comparable to that in the normal population. 
Hence, in Paper II we used the Swedish population to select a sex- and age-matched cohort 
based on death rates between 2008 and 2010. Among non-HDT patients that received novel 
agents in both first and second lines, 69% were alive after three years and 63% after five 
years whilst the corresponding figures in the matched cohort were 88% and 79% respectively, 
Figure 9B. The non-HDT group is thus approaching the survival in the normal population. 
 
Figure 9. Overall survival in non-HDT patients. (A) Patients treated with novel agents in 1st line are compared to those 
treated with conventional agents in 1st line as well as to a case-matched population. (B) Patients treated with novel 
agents in 1st and 2nd lines are compared to those treated with conventional agents in 1st and 2nd lines as well as to a 
case-matched population. B, bortezomib; T, thalidomide; L, lenalidomide. 
Seeing such good results for the MM population as a whole, we wondered if the survival 
benefits linked to novel treatment also were evident for patients with renal failure at 
diagnosis. As mentioned previously, renal failure is a frequent complication of MM. 
Furthermore, when using conventional chemotherapy renal impairment has been linked to 
increased morbidity and inferior survival [40,41]. From the study population used in Paper II 
we identified 1538 patients with known serum creatinine at diagnosis. Of these, 680 patients 
had renal impairment at diagnosis (i.e. eGFR <60 mL/min), Figure 7, and they were the main 
focus of Paper III. 
We showed that patients with renal impairment at diagnosis had a worse median OS than 
those with normal renal function (33 versus 52 months, P<0.001) and that the degree of renal 
impairment was correlated to OS (Figure 10), thus seemingly confirming that renal 
impairment is a risk factor. 
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Figure 10. Overall survival. The patients are divided according to the chronic kidney disease classification. 
However, with the use of novel agents as upfront treatment of patients not eligible for HDT 
the median OS was almost tripled compared to that seen after conventional chemotherapy 
(Figure 11A) and the same improvement was seen when analysing only the bortezomib 
treated patients. Multivariate analysis revealed that the difference remained highly significant 
after correction for age, calcium, haemoglobin and albumin. Moreover, with the use of novel 
agents we could no longer detect any difference in OS between non-HDT patients with and 
without RI, Figure 11B. These findings support earlier studies showing that the survival 
among patients with RI has improved since the introduction of novel agents [201] and that 
renal impairment is not an independent prognostic factor among newly diagnosed patients 
treated with novel agents [202]. 
 
Figure 11. Overall survival in non-HDT patients. (A) Patients with renal impairment treated with novel agents 
compared to conventional agents in 1st treatment line. (B) Patients with and without renal impairment treated with 
novel agents in 1st treatment line. 
The increased survival as well as prolonged TTNT might partly be explained by improved 
response rates after novel treatment compared to conventional chemotherapy, since a better 
disease control correlates to improved survival and PFS [201,203].  
In Papers II and III, we found better response rates after treatment with novel agents, 
which in Paper II was consistent through treatment lines 1–4. Moreover, in Paper II we 
could demonstrate that a good response in one treatment line predicted a good response in the 
following treatment line, at least until the fourth treatment line. We also found that TTNT 
was dependent on the depth of response (Table X), which correlates with results from 
previous studies [204]. 
!!!
A 
          Median           95% CI 
No    21 months      18 to 25 
Yes   60 months      43 to NR 
Log-rank P<0.001 
B
          Median           95% CI 
No    50 months      44 to 56 
Yes   60 months      43 to NR 
Log-rank P=0.86 
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Table X. Median TTNT (months) in non-HDT patients depending on depth of response. The 95% CI is also shown.  
P <0.001 in treatment line 1–3 and 0.085 in treatment line 4. 
 1st line  2nd line 3rd line 4th line 
All 17 (15–18) 12 (10–14) 9 (8–11) 7 (5–10) 
No response 13 (11–14) 8 (7–9) 8 (7–10) 5 (4–7) 
Partial response 18 (16–20) 16 (13–19) 11 (8–14) 10 (7–16) 
Very good partial response 
21 (20–32) 15 (11–18) 12 (8–16) 
 
15 (9–23) 
Near complete response 22 (16–29) 29 (13–32) 15 (7–26) 10 (6–20) 
 
Renal response is another factor that correlates to improved survival [205] as well as to 
myeloma response [206] and when renal response and myeloma response coincide the 
outcome improves compared to when they occur separately [205]. In Paper III, 
renal response was evaluated in 95 patients diagnosed and treated at Karolinska University 
Hospital, Figure 7. We found that a greater portion of the bortezomib treated patients 
improved their GFR compared to conventionally treated (92% versus 69%, P= 0.049), 
which corresponds with earlier studies [206,207]. 
4.3 HDT PATIENTS: NOVEL TREATMENT – A SHORT STORY  
The HDT population was the main focus of Paper I and was also part of Papers II and III. 
In Paper I, we could show that the VCB patients had a deeper response both before and after 
HDT (Figure 12) as well as a quicker response, Table XI. Our results are in line with those of 
other studies showing high response rates after induction with VCB [47,208]. However, 
in Paper II we could not quite confirm these findings, because even though patients treated 
with novel agents had a deeper response after the second and third treatment lines compared 
to those treated with conventional drugs, there was no significant difference after the first line 
of therapy. One explanation might be that the treatment in the HDT population in Paper II 
varied greatly. For instance, tandem-HDT as well as maintenance were more common among 
conventionally treated patients. 
The previously demonstrated high response rates after induction with VCB seem to persist 
even when the dose of bortezomib is decreased [48]. This is of course interesting since 
lowering the dose of a drug is one way of decreasing the risk of side effects, thus making it 
more likely that at larger proportion of the patients will tolerate the treatment. In this case it 
might mean that more patients will be able to proceed to HDT. In our study we unfortunately 
did not have any information on adverse events but only a few patients discontinued 
induction treatment, indicating limited toxicity. 
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Figure 12. Response rates before and after HDT. 
 
Table XI. Time to response (days) before HDT. There was a significant difference in both median time to first 
response and median time to best response between the two treatment groups, P<0.001.  
 VCB VAD/CyBet 
Median time to  
first response 
32 57 
Median time to  
best response 
43 65 
Range 8–133   9–195  
 
As mentioned above, the quality of response is an important factor that affects long-term 
outcomes such as PFS and OS. This finding is also supported by our data in Paper I 
because we found a significantly prolonged TTP in the VCB group compared to the 
VAD/CyBet group, Figure 13A. ISS stage, age and bone lesions were other factors that 
affected TTP according to univariate analysis. However, the multivariate analysis revealed 
that bone lesions were not an independent factor, whilst type of treatment, ISS stage and age 
were still significant. Likewise, there was a tendency towards a longer TTNT for the 
VCB treated patients for whom the median TTNT was not reached compared to 2.9 years in 
the VAD/CyBet group but this was not statistically significant. However, in Paper II we 
could demonstrate that TTNT was dependent on the depth of response (Table XII) and as for 
the non-HDT patients a good response in one treatment line predicted a good response in the 
following treatment line. However, the survival benefits from novel treatment seen in non-
HDT patients was not found among the HDT population, perhaps because the follow-up time 
was too short, Figure 13B. 
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Figure 13. Effect of VCB versus VAD or CyBet as induction treatment. (A) Time to progression. (B) Overall survival 
 
Table XII. Median TTNT (months) in HDT patients depending on depth of response. The 95% CI is also shown. 
P<0.05 in treatment line 1–4. 
 1st line  2nd line 3rd line 4th line 
All 33 (29–36) 10 (9–13) 8 (7–9) 7 (5–10) 
No response 18 (16–25) 6 (4–9) 5 (4–6) 3 (2–5) 
Partial response 25 (22–30) 10 (8–13) 10 (7–11) 8 (7–10) 
Very good partial response 29(26–42) 15 (8–17) 22 (8–23) 13 (5–18) 
Near complete response 45 (38–50) 18 (11–31) 13 (11–21) 32 (6–32) 
 
4.4 THE TRAIL TO RESISTANCE 
As discussed in Papers I–III, the use of novel agents, such as bortezomib, has lead to an 
improved outcome in MM patients. Nevertheless, around 20% of the patients do not respond 
to bortezomib [155]. We believe that this is partly due to del(8)(p21).  
Our group has previously demonstrated that del(8)(p21), which is found in approximately 
20% of newly diagnosed MM patients, is an independent factor associated with poor PFS and 
OS in MM patients receiving HDT [29,209]. In later published studies, del(8)(p21) has been 
further examined [210,211].  
Other studies have revealed that one of the effects of bortezomib is the upregulation of the 
pro-apoptotic TRAIL receptors 1 and 2 on the MM cells, thus making them more sensitive to 
apoptosis induced by TRAIL/APO2L [212]. The TRAIL receptor gene cluster is located on 
the short arm of chromosome 8. Alterations of the expression of TRAIL receptors on the cell 
surface due to del(8)(p21) could therefore cause decreased sensitivity of tumour cells to 
TRAIL-mediated apoptosis. However, since the deletion is usually monoallelic the cells still 
carry one copy of each TRAIL receptor gene. Hence, bortezomib might still upregulate the 
receptors and eradicate the MM cells. Furthermore, there are several other genes located on 
8p that might be involved in MM progression [213,214]. The aim of this study was therefore 
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to identify the consequences of del(8)(p21), especially in relationship to bortezomib treatment 
and TRAIL/APO2L-mediated killing.  
The mRNA levels of certain genes were analysed and compared between patients with 
(n=19) and without (n=6) del(8)(p21). Several differences were seen for genes located on or 
near the 8p21 region (Figure 14A) as well as for genes located elsewhere but with a 
functional link to genes located in this region (Figure 14B). Of these, some are of greater 
interest with regards to MM survival, for instance the overexpressed MYC oncogene which 
has been linked to MM cell survival [215-217] as well as the upregulation of PTK2B which 
promotes tumour progression [214]. The low expression of TP53 is of course also of interest 
[218]. We expected that the TRAIL receptor gene cluster would be affected, but we found 
similar expression levels of both the pro-apoptotic receptors TRAIL-R1, -R2 and the anti-
apoptotic decoy receptor TRAIL-R3. The only significant difference in expression at mRNA 
level was for the anti-apoptotic decoy receptor TRAIL-R4 which was upregulated in patients 
with del(8)(p21), Figure 15. When cell surface expression levels of the TRAIL receptors 
were analysed using flow cytometry similar results were seen. However, the upregulation of 
TRAIL-R4 in 8p21 deleted cells did not reach statistical significance, which might be 
explained by the fact that a smaller sample size was used for flow cytometric phenotyping. 
 
Figure 14. The relative mRNA level expression of genes in multiple myeloma cells with del(8)(p21) compared to those 
without the deletion. (A) Genes located on or near 8p21. (B) Genes located elsewhere on the chromosome but with a 
functional link to genes located on 8p21. 
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Figure 15. The relative mRNA level expression of TRAIL receptors in multiple myeloma cells with and without 
del(8)(p21). 
 
The MM cells where then treated in vitro with bortezomib for 24 hours and the TRAIL 
receptor expression was again analysed using flow cytometry. In MM cells from seven 
patients without del(8)(p21), bortezomib upregulated the expression of TRAIL-R1, thus 
making them more susceptible to TRAIL-mediated apoptosis. However, this was not seen in 
cells with del(8)(p21), Figure 16A. The expression of TRAIL-R2 and -R3 was not affected in 
MM cells with del(8)(p21), whilst the TRAIL-R3 was slightly upregulated in cells not 
carrying del(8)(p21). In MM cells with del(8)(p21), bortezomib tended to decrease the 
expression of TRAIL-R4 to the same levels as in cells without del(8)(p21), Figure 16B. 
We believe these changes seen in TRAIL receptor expression, due to bortezomib treatment, 
are myeloma specific because the expression of TRAIL receptors in the CD138-/CD45+ 
compartment of the BM was not affected by bortezomib treatment. 
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Figure 16. Relative cell surface expression of TRAIL receptors in MM cells from 6 patients with del(8)(p21) and 7 
patients without the deletion. The expression levels are normalized to corresponding isotype controls. (A) The pro-
apoptotic receptor TRAIL-R1. (B) The anti-apoptotic receptor TRAIL-R4. BTZ, bortezomib. 
 
Since bortezomib treatment failed to upregulate the pro-apoptotic TRAIL receptors in 
MM cells with del(8)(p21) we wondered whether this also made the cells less sensitive to 
TRAIL-mediated apoptosis. MM cells with and without del(8)(p21) were therefore treated 
with bortezomib and/or soluble TRAIL/APO2L. We found that bortezomib treatment alone 
and in combination with TRAIL/APO2L failed to induce apoptosis in MM cells with 
del(8)(p21) even though a slight downregulation of CD138 expression was seen. 
Downregulation of CD138 can be an early marker of apoptosis in MM cells [219] but in cells 
with del(8)(p21) it seems that the downregulation of CD138 expression does not trigger 
apoptotic pathways, thus indicating a possible apoptotic resistance mechanism. Conversely, 
in MM cells without del(8)(p21) apoptosis was seen after treatment with bortezomib and 
TRAIL/APO2L. The effect was seen when the two treatments were given separately and was 
significantly increased when bortezomib and TRAIL/APO2L were combined. 
Furthermore, we examined the clinical response of patients with and without del(8)(p21) and 
could confirm that patients with del(8)(p21) have a significantly shorter TTP and OS, 
Figure 17. In order to evaluate the effect of bortezomib we analysed non-HDT eligible 
patients that received bortezomib as upfront treatment (n=82). Patients carrying del(8)(p21) 
showed a very poor response to bortezomib with half of the patients not responding and only 
10% reaching VGPR, Figure 18A. On the other hand, patients without del(8)(p21) responded 
very well and the figures were reversed; 50% reached VGPR and only 10% did not respond, 
Figure 18A.  However, despite their poor response to bortezomib treatment, 
non-HDT patients with del(8)(p21) had a good response to lenalidomide as second line 
treatment (Figure 18B), indicating that this treatment could be preferred for this group of 
patients. 
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Figure 17. Overall survival from start of 1st treatment line in patients with (n= 37) and without (n=103) del(8)(p21). 
 
 
Figure 18. Response rate among non-HDT MM patients. (A) Response to upfront treatment with bortezomib.  (B) 
Response to 2nd treatment line among patients that received bortezomib in 1st treatment line and lenalidomide  
in 2nd treatment line. 
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5 CONCLUSIONS 
In the last 15 years, there has been a great development of treatment for MM. 
We demonstrate that the good results seen in clinical trials are also found in a real-life setting. 
More specifically we demonstrate that: 
• The combination of bortezomib, cyclophosphamide and betamethasone is a highly 
effective induction regimen with a rapid and deep response as well as prolonged TTP 
and post-HDT advantages compared to conventional chemotherapy. 
 
• The use of bortezomib, lenalidomide and thalidomide results in a higher response 
rate, increased TTNT and, most importantly, a longer OS compared to conventional 
agents in non-HDT patients. 
 
• The OS in the best non-HDT outcome group is closing the gap to the matched 
Swedish cohort but MM is not a chronic disease yet, especially not in younger 
patients. 
Concerning prognostic markers, we demonstrate that renal impairment is still an important 
prognostic marker in patients treated with conventional agents but we also show that novel 
agents can overcome the negative impact of renal impairment with improved OS survival in 
non-HDT patients. 
Twenty per cent of MM patients do not respond to bortezomib treatment. We demonstrate 
that changes associated with del(8)(p21) might be the foundation of resistance to bortezomib 
treatment and resistance against bortezomib-mediated sensitization to TRAIL/APO2L killing. 
These results are also supported by clinical data. 
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6 FUTURE PERSPECTIVES 
The future holds challenges and promises. 
There is a continuous and exciting development of new treatments for MM, for instance the 
new monoclonal antibodies targeting SLAMF7 and CD38 as well as the histone deacetylase 
inhibitors. Hopefully, this development of more efficient drugs will also make it possible to 
individualize the treatment for each patient. This might well be the saviour for those with 
myeloma as well as for an economic environment that has to take account of an aging 
population and therefore reduced margins of hospital care. 
The demands of efficiency will also inhibit the testing of expensive treatments with a small 
chance of succeeding, thus increasing the importance of knowing, in advance, who will 
benefit from a certain treatment and who will not. One example, which is given in this thesis, 
is the resistance to bortezomib seen in patients with del(8)(p21). It would be interesting to see 
if this could be generalised to other proteasome inhibitors such as carfilzomib. Our results 
also indicate that patients with del(8)(p21) benefit greatly from lenalidomide. This would be 
interesting to investigate further. 
Furthermore, with the ongoing discussion about starting MM treatment earlier it will become 
even more essential to know in which order treatments should be given. For this, large 
population-based studies are needed. Big Data, Data Mining and Data Warehousing will be 
crucial in the attempts to retrieve information from patients and control groups, amplified by 
the growing amounts of digital medical records and registered information of large groups in 
our society. Here, international cooperation will be of utmost importance and the possibility 
to combine data from different countries will most probably continue to be a growing field in 
basic research. 
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